Before the US stock market on Tuesday, Johnson & JohnsonAnnounced the third quarter of 2021 results.
Johnson & Johnson's third-quarter sales were $23.338 billion, up 10.7% from a year earlier, net profit was $3.667 billion, up 3.2% from a year earlier, and diluted earnings per share were $1.37, up from $1.33 a year earlier, according to the results.
By region, sales in the United States were $11.963 billion, up 7.9% from the same period last year, while sales in the international region were $11.375 billion, up 13.8% from the same period last year.
By business, the sales of the consumer health business were US $3.7 billion, up 5.3% from the same period last year; the sales of the pharmaceutical business were US $12.994 billion, up 13.8% from the same period last year, of which COVID-19 's vaccine sales were US $502 million; and the sales of the medical device business were US $6.644 billion, an increase of 8.0%.
The company raised its full-year 2021 guidance and expects adjusted operating sales to grow 9.9-10.5% year-on-year under basic business; operating sales range from $903 to $90.8 billion, up 9.4% from a year earlier; and reported sales are estimated to be between $916 and $92.1 billion, up 10.9-11.5% year-on-year.
Including COVID-19 vaccine sales, the company expects adjusted operating sales to increase by 12.9% to 13.5% year on year; operating sales to be between US $928 and US $93.3 billion, up 12.4%; and estimated reported sales to be between US $941 and US $94.6 billion, up 13.9% to 14.5% over the same period last year. Adjusted operating earnings per share (diluted) were between $9.65 and $9.70, up 20.2% and 20.8% over the same period last year, while adjusted diluted earnings per share were between $9.77 and $9.82, up 21.7% and 22.3% over the same period last year.
After the announcement of the results, as of press time, the stock rose 1.61% before trading to US $162.7.